The29F.1A12™-CP005monoclonal antibody is a recombinant chimeric version of the original 29F.1A12™，™antibody.The variable domain sequences are identical to the original 29F.1A12™but the constant region sequences have been switched from rat IgG2a to mouse IgG1。The29F.1A12™-CP005 antibody also contains a D265A mutation in the Fc fragment rendering it unable to bind to endogenous Fcγreceptors。29F.1A12™-CP005 reacts with mouse PD-1（programmed death-1）also known as CD279。PD-1is a50-55kDa cell surface receptor encoded by the Pdcdcd1gene that belongs to the CD28family of the Ig superfamily.PD-1is transiently expressed on CD4and CD8thymocytes as well as activated T and velymphocytes and myeloid cells.PD-1expression declines after successfuinal in in in in in in of Addigations cd1mRNA is expressed in developing B lymphocytes during the pro-B-cell stage.PD-1’s structure includes a ITIM（immunoreceptor tyrosine-based inhibitory motif）suggesting that PD-1negatively regulates TCR signals。PD-1signals via binding its two ligands，PD-L1and PD-L2both members of the B7family.Upon ligand binding，PD-1signaling inhibits T-cell activation，leading to reduced proliferation，cytokine production，and T-cell death.Additionally，PD-1is know to play proliferation，cytokine production production，T-cel death.Additionaly to plance of opertivance immune disease in mice as PD-1knockout animals show dilated cardiomyopathy，splenomegaly，and loss of peripheral tolerance.Induced PD-L1expression is common in many tumors including squamous cell carcinoma，colon adenocarcinoma，and breast adenocarcinoma.PD-L1overexpression ression ression ress increased resstance of tumoted is.In mouse models of melanoma，tumor growth can be transiently arrested via treatment with antibodies which block the interaction between PD-L1and its receptor PD-1.For these reasons anti-PD-1mediated immunotherapies are currently being explored as cancer treatments。
in vivoPD-1/PD-L签名* in vitroPD-1neutralization* Immunohistochemistry（frozen）* Immunofluorescence* Western blot* Flow cytometry* *Reported for the original rat IgG2a29F.1A12antibody
